Association of Maternal Age and Blood Markers for Metabolic Disease in Newborns
Pregnancy at an advanced maternal age is considered a risk factor for adverse maternal, fetal, and neonatal outcomes. Here we investigated whether maternal age could be associated with differences in the blood levels of newborn screening (NBS) markers for inborn metabolic disorders on the Recommende...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/14/1/5 |
| _version_ | 1827369581343145984 |
|---|---|
| author | Yuhan Xie Gang Peng Hongyu Zhao Curt Scharfe |
| author_facet | Yuhan Xie Gang Peng Hongyu Zhao Curt Scharfe |
| author_sort | Yuhan Xie |
| collection | DOAJ |
| description | Pregnancy at an advanced maternal age is considered a risk factor for adverse maternal, fetal, and neonatal outcomes. Here we investigated whether maternal age could be associated with differences in the blood levels of newborn screening (NBS) markers for inborn metabolic disorders on the Recommended Universal Screening Panel (RUSP). Population-level NBS data from screen-negative singleton infants were examined, which included blood metabolic markers and covariates such as age at blood collection, birth weight, gestational age, infant sex, parent-reported ethnicity, and maternal age at delivery. Marker levels were compared between maternal age groups (age range: 1544 years) using effect size analyses, which controlled for differences in group sizes and potential confounding from other covariates. We found that 13% of the markers had maternal age-related differences, including newborn metabolites with either increased (Tetradecanoylcarnitine [C14], Palmitoylcarnitine [C16], Stearoylcarnitine [C18], Oleoylcarnitine [C18:1], Malonylcarnitine [C3DC]) or decreased (3-Hydroxyisovalerylcarnitine [C5OH]) levels at an advanced maternal age (≥35 years, absolute Cohen’s d > 0.2). The increased C3DC levels in this group correlated with a higher false-positive rate in newborn screening for malonic acidemia (<i>p</i>-value < 0.001), while no significant difference in screening performance was seen for the other markers. Maternal age is associated with inborn metabolic differences and should be considered together with other clinical variables in genetic disease screening. |
| first_indexed | 2024-03-08T09:50:25Z |
| format | Article |
| id | doaj.art-025d778735684419a64f6e005cc465e1 |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-08T09:50:25Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-025d778735684419a64f6e005cc465e12024-01-29T14:04:30ZengMDPI AGMetabolites2218-19892023-12-01141510.3390/metabo14010005Association of Maternal Age and Blood Markers for Metabolic Disease in NewbornsYuhan Xie0Gang Peng1Hongyu Zhao2Curt Scharfe3Department of Biostatistics, Yale School of Public Health, New Haven, CT 06510, USADepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USADepartment of Biostatistics, Yale School of Public Health, New Haven, CT 06510, USADepartment of Genetics, Yale School of Medicine, New Haven, CT 06510, USAPregnancy at an advanced maternal age is considered a risk factor for adverse maternal, fetal, and neonatal outcomes. Here we investigated whether maternal age could be associated with differences in the blood levels of newborn screening (NBS) markers for inborn metabolic disorders on the Recommended Universal Screening Panel (RUSP). Population-level NBS data from screen-negative singleton infants were examined, which included blood metabolic markers and covariates such as age at blood collection, birth weight, gestational age, infant sex, parent-reported ethnicity, and maternal age at delivery. Marker levels were compared between maternal age groups (age range: 1544 years) using effect size analyses, which controlled for differences in group sizes and potential confounding from other covariates. We found that 13% of the markers had maternal age-related differences, including newborn metabolites with either increased (Tetradecanoylcarnitine [C14], Palmitoylcarnitine [C16], Stearoylcarnitine [C18], Oleoylcarnitine [C18:1], Malonylcarnitine [C3DC]) or decreased (3-Hydroxyisovalerylcarnitine [C5OH]) levels at an advanced maternal age (≥35 years, absolute Cohen’s d > 0.2). The increased C3DC levels in this group correlated with a higher false-positive rate in newborn screening for malonic acidemia (<i>p</i>-value < 0.001), while no significant difference in screening performance was seen for the other markers. Maternal age is associated with inborn metabolic differences and should be considered together with other clinical variables in genetic disease screening.https://www.mdpi.com/2218-1989/14/1/5maternal agenewborn metabolitesinborn errors of metabolismpublic healthnewborn screeningprecision medicine |
| spellingShingle | Yuhan Xie Gang Peng Hongyu Zhao Curt Scharfe Association of Maternal Age and Blood Markers for Metabolic Disease in Newborns Metabolites maternal age newborn metabolites inborn errors of metabolism public health newborn screening precision medicine |
| title | Association of Maternal Age and Blood Markers for Metabolic Disease in Newborns |
| title_full | Association of Maternal Age and Blood Markers for Metabolic Disease in Newborns |
| title_fullStr | Association of Maternal Age and Blood Markers for Metabolic Disease in Newborns |
| title_full_unstemmed | Association of Maternal Age and Blood Markers for Metabolic Disease in Newborns |
| title_short | Association of Maternal Age and Blood Markers for Metabolic Disease in Newborns |
| title_sort | association of maternal age and blood markers for metabolic disease in newborns |
| topic | maternal age newborn metabolites inborn errors of metabolism public health newborn screening precision medicine |
| url | https://www.mdpi.com/2218-1989/14/1/5 |
| work_keys_str_mv | AT yuhanxie associationofmaternalageandbloodmarkersformetabolicdiseaseinnewborns AT gangpeng associationofmaternalageandbloodmarkersformetabolicdiseaseinnewborns AT hongyuzhao associationofmaternalageandbloodmarkersformetabolicdiseaseinnewborns AT curtscharfe associationofmaternalageandbloodmarkersformetabolicdiseaseinnewborns |